bioihbjkbjnl/mcl2 huggingface dataset:
Latent Myofascial Trigger Points in the Craniocervical Region
Condition: Myofascial Pain Syndrome
MeSH terms: Myofascial Pain Syndromes; Fibromyalgia
Study type: Interventional

Summary: 
      Myofascial pain is a clinical problem that has generated interest, debate and confusion for
      decades. According to studies anywhere between 33 and 97 % of patients with musculoskeletal
      pain visiting physicians and manual therapists are diagnosed with Myofascial Trigger Points
      (MTrPs). MTrPs are localized, hyperirritable points that are associated with palpable nodules
      in taut bands (TB) of muscle fibres. MTrPs can be classified into active and latent. Latent
      MTrPs demonstrate the same clinical characteristics as active MTrPs but they do not provoke
      spontaneous pain. The myofascial trigger points (MTrPs) are common in healthy subjects and in
      patients with musculoskeletal pain, and could produce sensitive disturbances and motor
      dysfunctions
    


Intervention name(s): Neural mobilization; Soft tissue techniques and Stretching; Control group
Intervention type(s): Device; Device; Device
Intervention description(s): Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.; Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes; Did not receive any treatment.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: Trigger points; Trigegeminal nerve; Pain
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine
Condition: Growth Hormone Treatment; Aging
Study type: Interventional

Summary: 
      In a recent randomized, double-blind, cross-over clinical trial, serum growth hormone (hGH)
      increased 682% above baseline 120 minutes after oral administration of an amino acid-based
      dietary supplement (SeroVital), p=0.01 vs placebo. In contrast to the mechanism of hGH
      stimulation by ghrelin, the investigators hypothesize that the supplement suppresses
      somatostatin, a know inhibitor of both hGH and TSH. To test this hypothesis, the
      investigators measured triiodothyronine (T3) after administration of the amino acid-base
      supplement.
    

Detailed description: 
      Two molecular targets that regulate the synthesis and secretion of human growth hormone (hGH)
      include 1) ghrelin, an endogenous ligand secreted by the stomach that also has
      appetite-stimulation properties distinct from its hGH-stimulating effects, and 2)
      somatostatin, a family of 14 and 28 amino acid peptides that act as a potent noncompetitive
      inhibitor of the release of hGH. the investigators recently reported that oral administration
      of a 2.9g/dose of SeroVital, a blend of l-lysine HCl, l-arginine HCL, oxo-proline,
      N-acetyl-l-cysteine, l-glutamine, and schizonepeta (aerial parts) powder, leads to a
      significant 682% mean increase in endogenous hGH levels in male and female subjects in a
      period of 120 minutes following acute consumption. In the work presented here, the
      investigators seek to characterize the mechanistic target associated with this measured
      increase in endogenous hGH by SeroVital, which the investigators hypothesize to be
      somatostatin. The investigators test this hypothesis by assaying thyroid function, a
      secondary inhibition target of somatostatin. The investigators further compare our findings
      to ghrelin-based hGH secretagogues.
    

Intervention name(s): Amino acid supplement first day; Placebo first day; Amino acid supplement second day; Placebo second day
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): An orally administered supplement of the proprietary amino acid derivative; A non-active orally administered supplement of the proprietary amino acid derivative; An orally administered supplement of the proprietary amino acid derivative; A non-active orally administered supplement of the proprietary amino acid derivative
Other intervention name(s): SeroVital™; Non-active; SeroVital™; Non-active
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Somatostatin; Thyroid Hormone; Growth Hormone
Exercise Training and Inflammatory Mediators in COPD
Condition: COPD
Study type: Interventional

Summary: 
      Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is
      predicted to be the third leading cause of death by 2020[1]. COPD is a common, preventable
      treatable disease that is characterized by an airflow limitation which is not fully
      reversable[2].
    

Detailed description: 
      Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is
      predicted to be the third leading cause of death by 2020. COPD is a common, preventable
      treatable disease that is characterized by an airflow limitation which is not fully
      reversable.Not only the long-term exposition to noxious particles and gases contributes to
      the development of COPD, but also so many others factors such as genetics and cigarette
      smoking. It has been shown that cigarettes are harmful and contributed to different extra
      pulmonary disorders. Indeed, it induced a systemic inflammation that was considered as a key
      process in the pathogenesis of COPD and triggered the activation of inflammatory cells and an
      abnormal increase of circulating cytokines such as CRP, interleukin (IL6), IL8, tumor
      necrosis factor alpha (TNF alpha) and leptin.
    

Intervention name(s): Endurance Training ET; Resistance Training RT
Intervention type(s): Other; Other
Intervention description(s): Endurance training were prformed. Intensity was gradually increased.; Resistance training were prformed. Intensity was gradually increased.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Care Provider, Investigator)
Primary purpose: Treatment
Keywords: COPD; Inflammation; exercise training
Transesophageal Echocardiography(TEE) Probe Insertion and Tracheal Cuff Pressure
Condition: Intubation, Intratracheal
Study type: Interventional

Summary: 
      Tracheal cuff overinflation is known to reduce tracheal mucosal blood flow and to increase
      tracheal morbidity. Transesophageal echocardiography (TEE) probe insertion may increase the
      tracheal cuff pressure. The aim of this study is to evaluate the effect of TEE probe
      insertion on tracheal cuff pressure and to compare the effects in single-lumen tube and
      double-lumen tube.
    


Intervention name(s): balloon pressure adjustment
Intervention type(s): Procedure
Intervention description(s): Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction
Condition: Meibomian Gland Dysfunction
MeSH terms: Meibomian Gland Dysfunction
Study type: Interventional

Summary: 
      One of the important factors in obtaining successful outcomes when treating severe meibomian
      gland dysfunction (MGD) is to control the existing ocular and eyelid inflammation. Thus, in
      previous studies, topical and systemic antibiotics with anti-inflammatory function, such as
      topical azithromycin, systemic tetracycline, doxycycline and minocycline, have been used to
      treat severe MGD. In this study, minocycline which had the fewest side effects was used to
      evaluate the effect on cytokine levels in severe MGD. At study initiation, all patients
      completed an Ocular Surface Disease Index (OSDI) questionnaire and had an ocular surface,
      tear, and meibomian gland evaluation that consisted of fluorescein tear break-up time (TBUT),
      Schirmer test, corneal and conjunctival fluorescein staining, microscopic examination of lid
      margins and meibomian glands, and tear cytokine levels. All measurements except tear cytokine
      levels were conducted in the same manner before treatment, after 1 month, and after 2 months
      of treatment. Tear cytokine levels were evaluated before treatment and after 2 months of
      treatment. The aim of this research was to determine the concentration of inflammatory
      cytokines in the tears of patients with MGD and to compare the cytokine levels, corresponding
      clinical responses, and ocular symptoms before and after 2 months of treatment with oral
      minocycline.
    


Intervention name(s): oral minocycline hydrochloride treatment
Intervention type(s): Drug
Intervention description(s): Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
Intervention MeSH terms: Minocycline
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: meibomian gland dysfunction; inflammatory tear cytokine; minocycline
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
Condition: Still's Disease, Adult-Onset
MeSH terms: Arthritis, Juvenile; Still's Disease, Adult-Onset
Study type: Interventional
Phase: Phase 2

Summary: 
      The objective of this study is to assess safety, tolerability and early signs of efficacy of
      the investigational drug Tadekinig alfa in Adult-onset Still's disease, a rare polygenic
      auto-inflammatory disorder for which treatment remains empirical.

      This disease is characterized by a daily spiking fever, arthralgia / arthritis, and skin
      rashes with frequent components of sore throat, lymphadenopathies and neutrophilic
      leukocytosis. The etiology is unknown. In addition to the above-mentioned clinical features,
      the diagnosis includes some laboratory components that reflect the systemic inflammation:
      high erythro-sedimentation rate, C-reactive protein, high serum ferritin and high levels of
      interleukin 18 (IL-18).

      Tadekinig alfa is the drug name for recombinant human interleukin-18 binding protein
      (IL-18BP). This investigational drug was tested in healthy volunteers, psoriasis and
      rheumatoid arthritis patients in phase I studies. It demonstrated good safety and
      tolerability profile with only mild adverse events in the injection site.
    

Detailed description: 
      The hypothesis of this study considers high levels of IL-18 during active Adult-onset still's
      disease as the therapeutic target. Treatment with IL-18BP will permit to inhibit the
      pro-inflammatory cascade triggered by IL-18 and may help to manage the different components
      of the disease.

      This study is an open label, dose-finding study involving multiple centers in Europe. Two
      dose cohorts (80mg and 160mg) were treated during twelve weeks and followed-up for four more
      weeks.
    

Intervention name(s): Tadekinig alfa (recombinant human IL-18 binding protein)
Intervention type(s): Biological
Intervention description(s): Patients received the study treatment three times a week subcutaneously.
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Auto-inflammatory disease; Still's disease; Arthritis Rheumatoid; IL-18; interleukin-18; IL-18 binding protein
Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch
Condition: Glycogen Storage Disease Type IA; Glycogen Storage Disease Type IB; Glycogen Storage Disease Type III; Glycogen Storage Disease Type 0
MeSH terms: Glycogen Storage Disease; Glycogen Storage Disease Type III; Metabolic Diseases; Disease
Study type: Observational

Summary: 
      The aim of the present study is to determine if there is a change in quality and quantity of
      sleep perceived by adults and children with GSD and their parents while starting a modified
      UCCS (Glycosade) to prevent nocturnal hypoglycemia. The investigators also aim to evaluate if
      there is a change in quality of life perceived by adults and children and their parents with
      Glycosade.
    

Detailed description: 
      This is a prospective cohort study. Patients above 2 years old and their parents (for
      children only) will be enrolled during their usual follow-up. Parents will be asked to
      complete a quality of sleep questionnaire (as it pertains to both child and parent) relating
      to the past month on their current dietary regimen (standard UCCS) and a quality of life
      questionnaire (as it pertains to the child only). Parents will then complete a sleep diary
      (for both child and parent) and both child and parent will wear an actigraph that will record
      movements during sleep over a 1 week period. Adult GSD patients will complete their own
      questionnaires. Following this first assessment, they will be hospitalised over a 24 hour
      period as part of standard of care to start the modified UCCS, Glycosade, under supervision
      and with a continuous glucose monitoring (CGM) sensor. Following hospitalization, the family
      will return home. Glucose will be monitored with the aid of the CGM sensor for 5 to 7 days.
      The actigraphy and the sleep diary will be repeated after 2 weeks (for 1 week) while on
      Glycosade. One month after starting the modified UCCS, questionnaires on quality of sleep and
      quality of life will be repeated.
    

Intervention name(s): Glycosade
Intervention type(s): Dietary Supplement
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients with Glycogen Storage Disease taking uncooked cornstarch to prevent hypoglycemia
        followed at the Montreal Children's Hospital and St-Luc Hospital.
Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
MeSH terms: Carcinoma; Carcinoma, Hepatocellular
Study type: Interventional

Summary: 
      The aim of this study is to compare the surgical outcomes of cytoreductive surgery followed
      by Transarterial Chemoembolization (TACE) with TACE alone in patients with MNHCC so as to
      establish a treatment standard for MNHCC.
    

Detailed description: 
      Hepatocellular carcinoma (HCC) is one of the world's most common malignancies, especially in
      East-Asian countries. Hepatic resection has been accepted as the only means of cure for
      patients with HCC. The results of hepatic resection for early-stage HCC are
      favorable.Nevertheless, the role of surgical resection for multinodular HCC (MNHCC) is less
      well-defined.The presence of multiple tumors has been shown to be one of the most significant
      independent factors to influence cumulative survival rates in HCC after hepatic
      resection.Using the BCLC criteria,liver transplantation provides an alternative curative
      treatment option for MNHCC with size ≤ 5 cm in diameter and tumor number <3，but MNHCC beyond
      these criteria usually receive palliative therapy.

      For MNHCC which not suitable for curative treatment, non-surgical and surgical interventions
      are available for palliative care.Cytoreductive surgery has the potential to increase the
      quality and quantity of survival in patients with advanced HCC. Cytoreductive surgery is
      carried out with partial hepatectomy,cryosurgery,microwave coagulation therapy(MCT),or
      absolute alcohol injection.It has been shown to prolong survival and provide good symptomatic
      relief in patients with good surgical risks in non-randomized studies.Cytoreductive surgery
      aims at removal or destruction of all macroscopic tumours, allowing microscopic foci to
      persist while preserving as much of the functional liver tissue as possible. The development
      of effective local ablative therapy (LAT), such as radiofrequency ablation (RFA) therapy,
      facilitates reduction of the tumour burden even further during the operation.Cytoreductive
      surgery can also be followed by other non-surgical treatments,such as regional therapy or
      systemic therapy, to deal with the residual disease or micrometastases.

      The aim of this study is to compare the surgical outcomes of cytoreductive surgery followed
      by TACE with TACE alone in patients with MNHCC so as to establish a treatment standard for
      MNHCC.
    

Intervention name(s): Cytoreductive Surgery; TACE
Intervention type(s): Procedure; Procedure
Intervention description(s): Cytoreductive Surgery followed by TACE for MNHCC; TACE alone or TACE followed by downstage resection for MNHCC
Other intervention name(s): Cytoreductive group; TACE group
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cytoreductive
Desvenlafaxine in Opioid-Dependent Patients
Condition: Depression; Opioid Dependence; Methadone Treatment
MeSH terms: Opioid-Related Disorders; Depression; Depressive Disorder
Study type: Interventional
Phase: Phase 4

Summary: 
      Background: Although substitution therapy has been shown to be highly effective to retain
      opioid-dependent patients in treatment and reduce drug use, this population is afflicted by
      numerous conditions including depression. Unfortunately, studies published thus far have
      reported inconsistent or no difference in response between placebo therapy and
      antidepressants such as selective serotonin reuptake inhibitors. Objective: To assess the
      feasibility of Desvenlafaxine (DESV) administration among opioid-dependent subjects and
      explore its effect on depressive symptoms. Methods: Open-label pilot trial of 8 weeks of DESV
      50-100 mg/day in 20 methadone-maintained individuals with comorbid depressive symptoms at the
      Centre hospitalier de l'Université de Montréal. Significance: This pilot study will lay down
      the foundation on which a larger multisite clinical trial could be conducted to examine DESV
      as new treatment for opioid-dependent population with comorbid depression.
    

Detailed description: 
      To assess the feasibility, tolerability and acceptability of 8 weeks of Desvenlafaxine (DESV)
      administration among opioid-dependent subjects in a methadone-maintenance program, we will
      collect detailed information on compliance to DESV treatment, side effects, methadone plasma
      levels, methadone dose changes and QTc measures.

      To explore the effects of DESV on depressive symptoms among opioid-dependent subjects on
      methadone-maintenance treatment. The severity and symptoms of depression will be evaluated by
      using the MADRS, the HRDS, and the CGI scale.

      To explore the effects of DESV on substance use, anxiety, craving, quality of life and
      suicidal risk.
    

Intervention name(s): Desvenlafaxine
Intervention type(s): Drug
Intervention description(s): All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
Other intervention name(s): PRISTIQ
Intervention MeSH terms: Desvenlafaxine Succinate
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Desvenlafaxine; Opioid-dependent; Addiction; Depression; Methadone; Comorbidity
Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia
Condition: Chronic Obstructive Pulmonary Disease (COPD)
MeSH terms: Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate the safety, tolerability and efficacy of repeated
      inhalative doses of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.
    


Intervention name(s): Bimosiamose; Placebo
Intervention type(s): Drug; Drug
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
Condition: Vomiting
MeSH terms: Renal Insufficiency; Vomiting
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of the study is to evaluate how subjects with mild or moderate kidney problems
      process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
    


Intervention name(s): Casopitant
Intervention type(s): Drug
Intervention description(s): Casopitant oral tablets will be available with a dose of 50 milligrams.
Other intervention name(s): GW679769
Intervention MeSH terms: Casopitant
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: emesis; renal impairment; GW679769; kidney problems
Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting
Condition: Triple Vessel Disease; Unstable Angina; Stable Angina; Myocardial Infarction
MeSH terms: Myocardial Infarction; Angina Pectoris; Angina, Stable; Angina, Unstable; Infarction
Study type: Interventional

Summary: 
      In coronary artery bypass grafting, saphenous veins are widely used as a composite grafts
      that are Y-anastomosed to in-situ left internal thoracic artery. Based on our observation
      that remodeling of saphenous vein graft differs between those harvested from upper leg vein
      and lower leg, this study aims to compare histologic and immunohistochemical findings between
      saphenous vein grafts harvested from upper leg and lower leg.
    

Detailed description: 
      Inclusion criteria:

        -  Patients aged from 40 to 75 years with triple vessel disease

        -  Patients who are eligible for the use of left internal thoracic artery as an in situ
           primary conduit

        -  Operation plan: saphenous vein graft will be Y-anastomosed to left internal thoracic
           artery.

        -  Patients whose saphenous vein grafts can be harvested from both upper legs and lower
           legs

        -  Patients who are eligible for off-pump coronary artery bypass grafting

        -  Patients who agreed with the participation in the research based on thorough
           explanation.

      Patients will be randomly assigned to upper leg vein (ULV) group and lower leg vein (LLV)
      group immediately after anesthetic induction.

      Pieces of residual saphenous vein graft will be sent for histologic and immunohistochemical
      examination for the evaluation of endothelial cell preservation and the expression of matrix
      proteins.
    

Intervention name(s): Upper leg vein harvesting; Lower leg vein harvesting
Intervention type(s): Procedure; Procedure
Intervention description(s): Patients whose saphenous veins are harvested from upper legs.; Patients whose saphenous veins are harvested from lower legs.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: saphenous vein graft; composite graft; coronary artery bypass grafting; graft remodeling